IPW
CPRX

Impact Partnership Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

Impact Partnership Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-81
Closed -$1.09K – 1048
2023
Q2 		$1.09K Buy
+81
New +$1.17K ﹤0.01% 783

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Impact Partnership Wealth's CPRX Position: Q3 2023 in Review

Impact Partnership Wealth sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 81 shares — an estimated $1.09K sold.

Impact Partnership Wealth first reported a position in CPRX in Q2 2023 and held it in 1 quarter. The position peaked at $1.09K in Q2 2023. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Impact Partnership Wealth reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Impact Partnership Wealth sold 81 Catalyst Pharmaceutical shares in Q3 2023, an estimated $1.09K.
  • Impact Partnership Wealth first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 1 quarter.
  • Impact Partnership Wealth's Catalyst Pharmaceutical position peaked at $1.09K in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Impact Partnership Wealth's 13F filing for Q3 2023, filed 17 Oct 2023.